logo

EbookBell.com

Most ebook files are in PDF format, so you can easily read them using various software such as Foxit Reader or directly on the Google Chrome browser.
Some ebook files are released by publishers in other formats such as .awz, .mobi, .epub, .fb2, etc. You may need to install specific software to read these formats on mobile/PC, such as Calibre.

Please read the tutorial at this link:  https://ebookbell.com/faq 


We offer FREE conversion to the popular formats you request; however, this may take some time. Therefore, right after payment, please email us, and we will try to provide the service as quickly as possible.


For some exceptional file formats or broken links (if any), please refrain from opening any disputes. Instead, email us first, and we will try to assist within a maximum of 6 hours.

EbookBell Team

Cancer Immunotherapy At The Crossroads How Tumors Evade Immunity And What Can Be Done Current Clinical Oncology 1st Edition James H Finke Editor

  • SKU: BELL-2165146
Cancer Immunotherapy At The Crossroads How Tumors Evade Immunity And What Can Be Done Current Clinical Oncology 1st Edition James H Finke Editor
$ 31.00 $ 45.00 (-31%)

4.3

78 reviews

Cancer Immunotherapy At The Crossroads How Tumors Evade Immunity And What Can Be Done Current Clinical Oncology 1st Edition James H Finke Editor instant download after payment.

Publisher: Humana Press
File Extension: PDF
File size: 6.55 MB
Pages: 405
Author: James H. Finke (Editor), Ronald M. Bukowski (Editor)
ISBN: 9781588291837, 9781592597437
Language: English
Year: 2003
Edition: 1

Product desciption

Cancer Immunotherapy At The Crossroads How Tumors Evade Immunity And What Can Be Done Current Clinical Oncology 1st Edition James H Finke Editor by James H. Finke (editor), Ronald M. Bukowski (editor) 9781588291837, 9781592597437 instant download after payment.

Leading investigators and clinicians detail the different mechanisms used by tumors to escape and impair the immune system and then spell out possible clinical strategies to prevent or reverse tumor-induced immune dysfunction. The authors review the mechanisms of immune dysfunction and evasion mechanisms in histologically diverse human tumors, focusing on tumor-induced molecular defects in T cells and antigen-presenting cells (dendritic cells and tumors), that may serve as biomarkers for patient prognosis. They discuss the means by which these immune functions may be protected or restored in order to more effectively support the process of tumor rejection in situ. Cutting-edge techniques are outlined with the capacity to monitor the strength and quality of patients' immune responses using immunocytometry, MHC-peptide tetramers combined with apoptosis assay, ELISPOT assay, and detection of MHC-TAA peptide complexes on tumor cells.

Related Products